1,750
views
0
recommends
+1 Recommend
0 collections
    14
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials.

          Related collections

          Author and article information

          Journal
          J Clin Oncol
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          American Society of Clinical Oncology (ASCO)
          1527-7755
          0732-183X
          Apr 01 2008
          : 26
          : 10
          Affiliations
          [1 ] Amgen, Inc, One Amgen Center Dr, MS 38-2-B, Thousand Oaks, CA 91320-1799, USA. ramado@amgen.com
          Article
          JCO.2007.14.7116
          10.1200/JCO.2007.14.7116
          18316791
          70cf7ac4-49fa-44b0-ae13-c2125ece631f
          History

          Comments

          Comment on this article